Antibiotics such as antimycin A, oligomycin, and monoamine oxidase B (MAO-B) inhibitors used in Parkinson’s disease, and reactive oxygen species (ROS) inducers such as menadione have also been investigated for their potential to disrupt mitochondrial metabolism and reduce tumour viability [136–138]. This evidence concerns the gene MAOB and Parkinson disease.